Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor, AdultBRCA1 MutationBRCA2 MutationOvarian CancerBreast CancerProstate Cancer
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Acerand Therapeutics (Shanghai) Limited
- Target Recruit Count
- 298
- Registration Number
- NCT06380660
- Locations
- π¨π³
First Hospital Affiliated to Wenzhou Medical University, Wenzhou, Zhejiang, China
π¨π³Chongqing Cancer Hospital, Chongqing, Chongqing, China
π¨π³Henan Cancer Hospital, Zhengzhou, Henan, China
Β© Copyright 2025. All Rights Reserved by MedPath